NIS2+TM as a screening tool to optimize patient selection in metabolic dysfunction –associated steatohepatitis clinical trials

Strategies to reduce liver biopsy (LB) screen failures through better patient selection are needed for clinical trials. Standard fibrosis biomarkers were not derived to detect “at-risk” metabolic dysfunction–associated steatohepatitis (MASH; MASH with non-alcoholic fatty liver disease activity score ≥4 and fibrosis stage ≥2). We compared the performance of screening pathways that incorporate NIS2+™, an optimized version of the blood-based NIS4® technology des igned to identify at-risk MASH, with those incorporating fibrosis (FIB)-4 within the RESOLVE-IT clinical trial (NCT02704403), aiming for optimal selection of patients for LB.

Source: Journal of Hepatology - December 5, 2023 Category: Gastroenterology Authors: Vlad Ratziu, Stephen A. Harrison, Yacine Hajji, Jeremy Magnanensi, Stephanie Petit, Zouher Majd, Elodie Delecroix, Christian Rosenquist, Dean Hum, Bart Staels, Quentin M. Anstee, Arun J. Sanyal Source Type: research